SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending amid an earnings call reporting a substantial operating loss from Bitcoin impairments, fueling a sharp divide as some view it as a buying opportunity for leveraged BTC exposure while others warn of a failing 'ponzi scheme' given the asset's volatility.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

Iris Energy (IREN) is trending amidst a massive sell-off following its earnings report, which revealed a significant miss on revenue and EPS and lower-than-expected AI Cloud services revenue. While some in the community decry the results as a "scam" given the drastic price drop, others point to the company's reaffirmed long-term AI infrastructure targets, secured financing, and strategic shift away from Bitcoin mining as reasons for optimism despite broader sector pressure.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending amid a sharp price decline and mass liquidations, with community discussion heavily influenced by recently surfacing Epstein files, leading to widespread debate over its underlying value and whether current levels signal a generational buying opportunity or further collapse.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending following its recent financial results, as robust growth in AWS and overall revenue are overshadowed by a substantial future capital expenditure forecast for AI and other innovative technologies. This aggressive investment plan is generating significant market debate, with investors divided between concerns over immediate returns and viewing the pullback as a long-term buying opportunity.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is experiencing a sharp market downturn, reflecting broader cryptocurrency weakness, as the community debates whether institutional manipulation or fundamental shifts are driving the extensive sell-off. While many express panic over significant portfolio losses, a strong contingent views current levels as a prime accumulation phase for long-term potential, eagerly awaiting further dips to buy the fear.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPDR S&P 500 ETF Trust is trending significantly lower, driven by a broad tech sector rout that intensified after major companies like Amazon experienced post-earnings drops. The community is expressing overwhelmingly bearish sentiment, questioning the immediate profitability of massive AI capital expenditures and discussing a widespread "risk-off" shift across equities and crypto markets.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is a major talking point as the tech sector experiences a broad sell-off, fueled by investor concerns over mega-cap AI capital expenditure, notably from Amazon, and a wider market reevaluation of growth versus profitability, which the community is actively debating as a potential market reset.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is at the center of investor conversation following a sharp decline, sparking intense debate over whether the sell-off is an unwarranted market overreaction or manipulation, especially given major hyperscalers' recently announced massive capital expenditures for AI infrastructure, with all eyes now on upcoming earnings.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull (BULL) is trending due to a significant and sustained price decline, with community members attributing the drop to broader market corrections and a strong, albeit questioned, correlation with recent cryptocurrency pullbacks. Intense discussion highlights investor frustration, speculation about market manipulation, and a sharp divide between those advocating to "buy the dip" and others warning of a "falling knife" amidst calls for management to address the ongoing downturn.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining (CIFR) is heavily discussed as it navigates sector volatility, with a recent $2 billion senior secured notes offering for its Amazon-leased Black Pearl data center fueling its strategic expansion into AI infrastructure. While the community debates market manipulation and Bitcoin's impact, investors emphasize CIFR's significant hyperscaler contracts and low-cost power as core strengths for its pivot to high-performance computing.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>For Genius Sports, the transaction is expected to be immediately accretive to group adjusted core profit and free cash flow conversion.&nbsp;</li><li>Genius Sports said its prelim group revenue for FY25 is of $669 million, reflecting 31% year-on-year growth.</li><li>It also expects to generate group revenue of approximately $810-820 million in FY26.</li></ul>Genius Sports (<a href="https://stocktwits.com/symbol/GENI">GENI</a>) shares plunged on Thursday after it announced it has entered into a definitive agreement to acquire Legend, a global, digital sports and gaming media network.Shares plunged 26.5% to $6.28 at the time of writing and garnered retail chatter around the deal.<h2 class="st-heading-2">Deal Details</h2>Genius Sports said it is acquiring Legend in a transaction valued at up to $1.2 billion, including $900 million payable at closing and an earnout of up to $300 million.For Genius Sports, the transaction is expected to be immediately accretive to group adjusted core profit margins and free cash flow conversion while maintaining at least 20% group revenue compound annual growth rate (CAGR) through 2028.&nbsp;On a 2026 annualized pro forma basis; after giving effect to the acquisition, the combination is expected to position Genius to achieve approximately $1.1 billion in group revenue, $320-330 million in group adjusted core profit with approximately 50% free cash flow conversion.“This deal accelerates our strategic and financial objectives, supercharges fan monetization, and builds a fully integrated sports and gaming media network,” said Mark Locke, CEO of Genius Sports.<h2 class="st-heading-2">Prelim FY25 Earnings And FY26Outlook</h2>The company on Thursday also reported its preliminary unaudited financial results for the fiscal year ended December 31, 2025. It said its prelim group revenue is $669 million, reflecting 31% year-on-year growth.Genius Sports also expects to generate group revenue of approximately $810-820 million, and group adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of approximately $180-190 million in 2026 on a standalone basis.&nbsp;Group Revenue of $1.6 billion, representing approximately 21% compound annual growth rate (CAGR) from 2026 to 2028, as the acquisition and integration of Legend will also set a higher performance benchmark for 2028, it said in a statement.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around GENI trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;One user on Stocktwits opined that they are not sure that GENI needed to inject this risk as its business was doing well.&nbsp;<stembedurl>https://stocktwits.com/Windy007/message/644135227</stembedurl>Another user said they were not expecting the company to strike a more than $1billion worth deal.<stembedurl>https://stocktwits.com/Jblack500/message/644132457</stembedurl>Shares in the company have fallen 34% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-coin-stock-down-today/cZbZWG7R4Vz">Why is COIN Stock Falling More Than 8% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Shares of GENI plunged 26.5% to $6.28 at the time of writing and garnered retail chatter around the deal.

Genius Sports’ Stock Is Down 26% Today – Why Is Retail Wary?

 Genius Sports said it is acquiring Legend in a transaction valued at up to $1.2 billion, including $900 million payable at closing and an earnout of up to $300 million.

Equity

<ul class="summary-bullets"><li>The first product on the list is Hydrelix, a Type 1 collagen powder that provides the bioactive components of collagen at the wound site.</li><li>The second product is NovaForm Wound Matrix, a bioglass- and collagen-based wound dressing intended for the management of partial- and full-thickness wounds.</li><li>Summit will also distribute G4Derm Plus, a flowable peptide matrix engineered for rapid, protected wound closure.</li></ul>MiMedx Group Inc. (MDXG) shares gained around 5% in Wednesday morning’s trade after the company entered into an exclusive distribution agreement with Summit Products Group for three of its 510(k) cleared products.According to the agreement, Summit will distribute Hydrelix, NovaForm, and G4Derm Plus, designed to complement MiMedx’s portfolio of leading surgical and wound products.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/MDXG">MiMedx</a> was in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels.<h2 class="st-heading-2">What Will Summit Distribute?</h2>The three products included in the agreement are intended to care for and enhance the closure of wounds.The first product in the list is Hydrelix, which is a Type 1 collagen powder that allows the bioactive components of collagen to be readily available at the wound site, facilitating a more direct and efficient therapeutic effect.The second product is NovaForm Wound Matrix, which is a bioglass and collagen-based wound dressing intended for use in the management of partial and full-thickness wounds. NovaForm can be used for pressure ulcers, venous ulcers, diabetic ulcers, and surgical wounds.&nbsp;The company says NovaForm is designed to maintain a moist environment that supports the body’s natural healing process while protecting the wound.Lastly, Summit will also distribute G4Derm Plus, a flowable peptide matrix engineered for rapid, protected wound closure, spurring tissue regrowth, and controlling bioburden. The company stated that G4Derm Plus mimics the human extracellular matrix (ECM) and acts as a barrier against bacteria.“These are innovative xenograft and synthetic products that strengthen our ability to serve the Surgical &amp; Wound markets,” said MiMedx’s Chief Commercial Officer, Kim Moller.<h2 class="st-heading-2">What Does MiMedx Do?</h2>MiMedx is a Marietta, Georgia-based company with a portfolio of surgical and wound care products designed to help clinicians manage chronic and other hard-to-heal wounds.In December 2025, the company entered into an exclusive agreement with Regen Lab USA LLC to distribute the latter’s RegenKit-Wound Gel in the U.S.<a href="https://stocktwits.com/symbol/MDXG">MDXG stock</a> is down 24% year-to-date and 40% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amazon-openai-in-talks-to-customize-ai-models/cZbjTCvR4Zu">Amazon, OpenAI In Talks To Customize AI Models To Power E-commerce Giant's Products Such As Alexa: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

MDXG Stock Rises As MiMedx Enters Into Exclusive Distribution Agreement For Three Products

According to the agreement, Summit Products Group will distribute Hydrelix, NovaForm, and G4Derm Plus, designed to complement MiMedx’s portfolio of leading surgical and wound products.

<ul class="summary-bullets"><li>The report alleged that golfer Phil Mickelson was among the select investors.</li><li>Sable said it is providing documents and cooperating with requests from the government.</li><li>Sable also entered into a sales agreement with TD Securities and Jefferies to sell up to $250 million of common stock.</li></ul>Shares of Sable Offshore Corp. (SOC) plunged over 10% on Tuesday after the company revealed it had received subpoenas from the U.S. Attorney’s Office for the Southern District of New York and the SEC, following a Hunterbrook investigation alleging selective disclosure of material information to certain investors.The company also announced a $250 million share sale agreement.In an SEC filing, Sable said it received the subpoenas on December 2, weeks after Hunterbrook’s October 31 report. The report alleged that CEO Jim Flores shared multiple updates privately with select investors, including golfer Phil Mickelson.One such update was that the company may need to raise up to $200 million in equity by the end of 2025. Sable said it is providing documents and cooperating with government requests.<h2 class="st-heading-2">Sable’s $250 Million Share Sale Plan</h2>Sable also entered into a sales agreement with TD Securities (USA) LLC and Jefferies LLC, which will allow the company to sell up to $250 million of its common stock through an at-the-market (ATM) offering.&nbsp;Last month, California Attorney General Rob Bonta sued the Donald Trump administration over the planned restart of two onshore oil pipelines owned and operated by Sable. The lawsuit challenged federal orders that assert exclusive jurisdiction over the Las Flores pipelines. Bonta argued the pipelines run within California and should remain under state oversight, citing environmental risks.The lines have been shut down for a decade following the 2015 Refugio Beach oil spill, which released hundreds of thousands of gallons of crude.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bearish’ from ‘bearish’ a day earlier. One user said the stock’s decline was an overreaction by the market.<stembedurl>https://stocktwits.com/s66666/message/643781913</stembedurl>Year-to-date, <a href="https://stocktwits.com/symbol/SOC">SOC shares</a> have declined around 25%.Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-tirx-stock-surge-today/cZbiyMWR4m9">This Nano-Cap Insurance Stock Surged Over 200% Today – What Is The Bitcoin Connection?</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

SOC Stock Declines 10% – What Are The Factors Driving The Selloff?

The company disclosed that it has received subpoenas from the U.S. Attorney’s Office for the Southern District of New York and the SEC on reports of selective disclosure of material information to certain investors.

<ul class="summary-bullets"><li>The FDA’s concerns were limited to packaging, labeling, and administration issues, the company said.</li><li>Aquestive has already modified the pouch design, updated instructions for use, and revised labelling.</li><li>The firm is also targeting global expansion plans for Anaphylm after initiating regulatory discussions in Canada, Europe, and the U.K last year.</li></ul>Shares of Aquestive Therapeutics (AQST) surged more than 35% on Monday morning, after receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) seeking approval of Anaphylm, a sublingual film to treat severe Type I allergic reactions.A CRL indicates that while a drug has not been approved in its current form, it allows the sponsor to address the issues raised by the FDA and seek re-approval.<h2 class="st-heading-2">FDA’s Concerns</h2>The FDA’s concerns were limited to packaging, labeling, and administration issues identified in a human factors validation study. The FDA noted that some users had difficulty opening the pouch and correctly placing the film, which could pose safety risks during emergency situations. The agency did not raise questions about the drug’s comparability data or manufacturing processes, the company said.To address the feedback, Aquestive has modified the pouch design, updated instructions for use, and revised labeling. The company plans to conduct a new human factors study alongside a single pharmacokinetics (PK) study requested by the FDA. No additional trials are required.Based on the initial review, Aquestive expects to resubmit the application as early as the third quarter of 2026 and will seek a rapid review.<h2 class="st-heading-2">Europe Update</h2>Aquestive is also targeting global expansion plans for Anaphylm after initiating regulatory discussions in Canada, Europe, and the U.K. in 2025. The European Medicines Agency indicated that no additional clinical trials are required, with submissions in Europe and Canada expected in the second half of 2026. The company also anticipates feedback from the U.K.’s MHRA in the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ a session earlier, amid ‘high’ message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/AQST_jpg_c092cd62f6.webp" alt="AQST.jpg">One user brushed off concerns about the CRL, noting there were no key issues.<stembedurl>https://stocktwits.com/BigGainTom/message/643649716</stembedurl>While the stock has gained nearly 35% over the past year, its year-to-date losses are around 40%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/precious-metals-extend-historic-rout/cZbg8EJR4kf">Gold, Silver Continue To Decline – Analysts Warn Of Crowded Trades As Precious Metals Extend ‘Historic Rout’</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did AQST Stock Jump 35% Today?

The company received a Complete Response Letter from the U.S. Food and Drug Administration for its New Drug Application seeking approval of Anaphylm, a sublingual film to treat severe Type I allergic reactions.

<ul class="summary-bullets"><li>The U.S. Food and Drug Administration did not request any additional clinical studies or new patient data, as per the company.</li><li>Capricor now plans to submit the data requested by the FDA in February.</li><li>CEO Linda Marbán said that the company is “pleased” that the FDA requested the clinical study report, adding that the request was expected.</li></ul>Shares of Capricor Therapeutics (CAPR) fell 2% on Tuesday morning after the company said that the U.S. Food and Drug Administration (FDA) has requested more data from its trials of Deramiocel.In July, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/capricor-therapeutics-stock-sparks-retail-frenzy-as-traders-hail-best-data-ahead-of-dmd-data-rollout/cLI7F7XRE0P">refused</a> to approve Capricor’s application for Deramiocel for the treatment of Duchenne muscular dystrophy, stating that it does not meet the requirement for substantial evidence of effectiveness, while also expressing the need for additional clinical data. The company said at the time that it intends to meet the FDA’s additional clinical data requirement with a late-stage study and resubmit its application.In December, the company provided the FDA with results from its late-stage HOPE-3 study in which Deramiocel delivered strong signals of benefit for muscle and heart function. However, after reviewing the data, the FDA has formally requested the full HOPE-3 clinical study report (CSR) and supporting data, Capricor said on Tuesday. The agency, however, did not request any additional clinical studies or new patient data, it <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/335/capricor-therapeutics-provides-regulatory-update-on">added.</a><h2 class="st-heading-2">Fresh Timelines</h2>Capricor now plans to submit the new data requested by the FDA in February and expects that the submission will support continued review of its application and address the concerns raised by the FDA in July. &nbsp;CEO of Capricor, Linda Marbán, said that the company is “pleased” that the FDA requested the clinical study report, adding that the request was expected.“Our near-term priority is to address the FDA’s request and continue working collaboratively so that patients with late-stage DMD, who currently have very limited treatment options, may gain access to Deramiocel as soon as possible,” Marbán added.DMD is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock stayed within the ‘bearish’ territory while message volume stayed at ‘low’ levels.A Stocktwits user voiced optimism for the drug getting approved in the following three to five months.<stembedurl>https://www.stocktwits.com/jamestrade07/message/642322958</stembedurl>Another user voiced hopes for the stock touching as much as $100 by end of year following Deramiocel approval.<stembedurl>https://www.stocktwits.com/haha1978/message/642314942</stembedurl><a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained 69% over the past 12 months. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/moderna-shares-rise-on-five-year-follow-up-takeaways-for-skin-cancer-vaccine/cmUuq4QR4OT">Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think?

The FDA has formally requested the full HOPE-3 clinical study report (CSR) and supporting data, Capricor said on Tuesday. 

<ul class="summary-bullets"><li>As per the deal, Bakkt will issue about 9.1 million shares of Class A common stock to DTR shareholders.&nbsp;</li><li>Acquisition of DTR advances Bakkt’s global stablecoin settlement and programmable payments strategy.&nbsp;</li><li>Separately, it said that it intends to change its corporate name to ‘Bakkt, Inc’ effective January 22, 2026.&nbsp;</li></ul>Shares of Bakkt (BKKT) rallied on Monday after it announced that it has agreed to acquire Distributed Technologies Research (DTR), a global stablecoin payment infrastructure provider.As per the deal, and as consideration for DTR, Bakkt will issue shares of its Class A common stock representing 31.5% of the “Bakkt Share Number,”. Bakkt will issue about 9.1 million shares of Class A common stock to DTR shareholders, it said in a statement.&nbsp;“We are pleased to welcome DTR to Bakkt,” said Colleen Brown, Director and member of the Special Committee of Bakkt’s Board of Directors. “This transaction accelerates Bakkt’s evolution toward programmable money and new-age global financial infrastructure and reflects a disciplined approach to capital allocation aligned with long-term platform value creation”.&nbsp;<h2 class="st-heading-2">Push Towards Stablecoin</h2>Acquisition of DTR advances Bakkt’s global stablecoin settlement and programmable payments strategy. Bakkt has been undergoing a strategic pivot in recent months to get into crypto space. It has also launched a crypto treasury.&nbsp;The firm sold its loyalty rewards business last year and began acquiring money transmitter licenses to facilitate crypto trading, transfers, and settlement. The company provides solutions that enable institutional participation in the digital asset economy — spanning Bitcoin, tokenization, stablecoin payments, and AI-driven finance.&nbsp;Bakkt announced that it intends to change its corporate name to ‘Bakkt, Inc’ effective January 22, 2026. The company expects to continue to trade on the New York Stock Exchange under the ticker symbol ‘BKKT’.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around BKKT trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;One user said that it will not sell the stock until at least it reaches $150.<stembedurl>https://stocktwits.com/Safetyisfirst/message/641569194</stembedurl>Another bullish user predicted the stock to touch $30 by the end of the week.<stembedurl>https://stocktwits.com/Egreenebacks/message/641557360</stembedurl>Shares of Bakkt have fallen 20% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the Bakkt Holdings logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Bakkt Stock Rallies Nearly 20% - What’s Behind The Move?

Bakkt said it has agreed to acquire Distributed Technologies Research, a global stablecoin payment infrastructure provider. 

<ul class="summary-bullets"><li>Sweden will own a customized suite of Planet Labs satellites and have access to the company’s high-resolution imagery and analytics.</li><li>Planet Labs said the revenue from the deal will be recognized over several years and that this does not change its previously issued Q4 guidance.</li><li>Over the past twelve months, Planet Labs has signed more than $500 million in satellite services contracts.</li></ul>Shares of Planet Labs PBC (PL) jumped 7% on Monday after the company secured a multi-year, low nine-figure contract with the Swedish Armed Forces to deliver satellites, space-based data, and intelligence solutions.Under the agreement, Sweden will own a customized suite of Planet Labs satellites and have access to the company’s high-resolution imagery and analytics.“Europe needs its own eyes, and Sweden is leading the way by rapidly securing its own, comprehensive space capability – helping achieve its own security objectives and assisting regional allies, like Ukraine, with timely, critical information,” said Will Marshall, Planet Labs CEO and co-founder.&nbsp;<h2 class="st-heading-2">Financial Outlook</h2>Planet Labs said that revenue from the Swedish partnership will be recognized over several years and that this does not change its previously issued fourth-quarter (Q4) guidance. The company expects revenue of $76 million to $80 million in Q4, with gross margins of 50% to 52% and an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) loss of $5 million to $7 million.For the full fiscal year 2026, Planet Labs’ revenue is forecast between $297 million and $301 million, while adjusted EBITDA is forecast to come in between $6 million and $8 million.<h2 class="st-heading-2">Global Partnerships</h2>Over the past twelve months, Planet Labs has signed more than $500 million in satellite services contracts.In May, the German Federal Agency for Cartography and Geodesy (BKG) signed a seven-figure, one-year contract with Planet Labs, with an option to extend for two more years.The deal gives BKG access to Planet Labs’ data over Germany, supporting environmental, agricultural, and land-use monitoring.Planet Labs signed a seven-figure NATO contract in June and renewed a $7.5 million U.S. Navy deal to provide advanced monitoring and vessel detection across the Pacific.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ over the past 24 hours. <a href="https://stocktwits.com/symbol/PL">PL</a> was also among the top trending tickers at the time of writing.<img src="https://news.stocktwits-cdn.com/PL_jpg_f247675df5.webp" alt="PL.jpg">One bullish user predicts the company will secure numerous global contracts, potentially driving the share price up to $60.<stembedurl>https://stocktwits.com/Counselor53/message/641531232</stembedurl>Another user believes the company could be the next Rocket Lab.<stembedurl>https://stocktwits.com/ryanbolin2001/message/641529291</stembedurl>Over the past year, the PL stock has surged more than 550%.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-sofi-afrm-stocks-are-rising-today/cmUacDhR4EW">Why Analysts See SoFi, Affirm Benefiting From A Credit Card Rate Cap</a>&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone held in a hand shows the logo of Planet Labs PBC

Planet Labs Stock Gained 7% Today — What Is The Swedish Military Deal About?

The company secured a multi-year, low nine-figure contract with the Swedish Armed Forces to deliver satellites, space-based data, and intelligence solutions.

<ul class="summary-bullets"><li>Anaphylm is Aquestive’s sublingual epinephrine film for allergic reactions.</li><li>The Anaphylm application is supported by 11 clinical studies involving 411 subjects, the company said.</li><li>Aquestive is working with the agency to better understand and address the issues ahead of the PDUFA date on January 31, it added.</li></ul>Shares of Aquestive Therapeutics (AQST) plunged 40% in pre-market trading on Friday after the company announced that it received a letter from the U.S. Food and Drug Administration (FDA) identifying deficiencies that currently prevent labeling discussions on Anaphylm.Anaphylm is Aquestive’s sublingual (under the tongue) epinephrine film for allergic reactions.However, the FDA also confirmed its review of the New Drug Application (NDA) remains ongoing, and no final decision has been made.Aquestive is working with the agency to better understand and address the issues ahead of the PDUFA (Prescription Drug User Fee Act) date on January 31, noting that delays in receiving details could impact the approval timeline. A PDUFA date is the FDA's target date to make a decision on a drug application.The Anaphylm application is supported by 11 clinical studies involving 411 subjects, demonstrating pharmacokinetics comparable to epinephrine auto-injectors and a similar safety profile, Aquestive added.“As part of its ongoing review of the Company’s NDA for Anaphylm, the FDA notified us that it had identified deficiencies in the NDA that preclude discussion of labeling and post-marketing commitments at this time. Although the notification did not specify the deficiencies, Aquestive is working to understand and resolve the concerns. The FDA stated that the notification does not reflect a final decision on the pending application and the FDA’s review remains ongoing,” said Dan Barber, President and Chief Executive Officer of Aquestive.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the strong intraday decline, retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/AQST">AQST</a> turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/AQST_jpg_2de986106b.webp" alt="AQST.jpg">Over the past year, the stock has gained 23%.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Plug Power said it was impacted by the speed and development of hydrogen economy.

Why Did AQST Stock Plunge 40% In Pre-Market Today?

The company said the U.S. FDA identified deficiencies that prevent labeling discussions for a drug to treat allergic reactions.

AQST Stock Plunges On An FDA Setback For Its Allergy Drug – Here’s What Has Changed 

<ul class="summary-bullets"><li>Northrop Grumman secured the competitive award for the MUX TACAIR aircraft, with Kratos’ Valkyrie drone forming a core part of the solution.</li><li>Kratos’ Valkyrie uncrewed aerial system enables operators to tailor mission effects to operational needs.</li><li>Kratos also voiced its backing for President Trump’s renewed emphasis on using defense industry funds for capability development.</li></ul>Kratos Defense &amp; Security Solutions, Inc. (KTOS) has landed a key role in a new U.S. Marine Corps effort to expand uncrewed combat aviation, teaming with Northrop Grumman Corp. (NOC).Following the update,&nbsp;<a href="https://stocktwits.com/symbol/KTOS">Kratos’ stock</a> traded more than 15% higher by mid-morning on Thursday. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory while message volume improved to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_08_104845_png_c27dd72ad7.webp" alt="KTOS’s Sentiment Meter and Message Volume as of 10:45 a.m. ET on Jan. 8, 2026 | Source: Stocktwits" width="926" height="102"><figcaption>KTOS’s Sentiment Meter and Message Volume as of 10:45 a.m. ET on Jan. 8, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Collaborative Combat Aircraft (CCA)</h2>Northrop Grumman secured the competitive award for the Marine Air-Ground Task Force Uncrewed Expeditionary Tactical Aircraft, known as MUX TACAIR, with Kratos’ Valkyrie drone forming a core part of the solution.Under the program, Northrop Grumman will lead development and delivery of an uncrewed platform that blends its autonomous technologies with Kratos’ Valkyrie aerial system.&nbsp;The aircraft is designed to fly in coordination with crewed fighters, supporting air dominance missions in high-threat environments. Kratos’ Valkyrie uncrewed aerial system allows operators to tailor mission effects depending on operational needs.<h2 class="st-heading-2">Support For Capital Choices</h2>Kratos also voiced its backing for President Trump’s renewed emphasis on using defense industry funds for capability development rather than share repurchases by defense contractors.<blockquote>“Since our inception as a defense company, we have aggressively self-funded development to be first-to-market with relevant systems that can be affordably produced in large quantities to deter and, if necessary, defeat our adversaries, and we have reinvested in people, facilities, inventory, and real technologies that can be delivered at speed and scale to support today’s and tomorrow’s warfighter.”-Eric DeMarco, President and CEO, Kratos</blockquote>The company underscored that it has long pursued a reinvestment-focused financial model that avoids share buybacks and dividends, allocating capital instead to advancing battlefield technologies.KTOS stock has gained over 271% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/smx-stock-sparks-retail-buzz-after-elimination-of-convertible-debt/cmUbORER45R">SMX Stock Sparks Retail Buzz After Elimination Of Convertible Debt</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, a person holds a smartphone displaying the logo of Kratos Defense & Security Solutions Inc. 

Why Did Kratos Defense Stock Surge 17% Today?

Under the Marine Corps program, Northrop Grumman will lead the development and delivery of an uncrewed platform that blends its autonomous technologies with Kratos’ Valkyrie aerial system.

<ul class="summary-bullets"><li>The outlook includes $150 million to $170 million from DefenCath, with results weighted toward the first half of the year.</li><li>The company expects adjusted EBITDA for 2026 to be between $100 million and $125 million.</li><li>CorMedix is commercializing a portfolio of anti-infective products.</li></ul>Shares of CorMedix Therapeutics (CRMD) plunged 28% on Thursday after the company issued a cautious full-year 2026 outlook, signalling revenue could come in below 2025 levels.<a href="https://stocktwits.com/symbol/CRMD">CRMD</a> was among the top trending stocks at the time of writing.CorMedix posted net revenue of around $127 million in the fourth quarter (Q4) of 2025 and $310 million for the full year, with pro forma full-year revenue of about $400 million. Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) for Q4 is expected to range between $77 million and $81 million.<h2 class="st-heading-2">Full-Year Expectations</h2>For 2026, CorMedix expects revenue between $300 million and $320 million, including $150 million to $170 million from DefenCath, with performance weighted toward the first half of the year. DefenCath is an FDA-approved catheter lock solution used to reduce bloodstream infections in certain adult dialysis patients with central venous catheters.Adjusted EBITDA for 2026 is projected at $100 million to $125 million, supported by $35 million in annualized cost synergies from the Melinta acquisition. Last August, CorMedix acquired Melinta Therapeutics in a $300 million deal, which also includes up to $25 million in regulatory milestone payments and royalties.<h2 class="st-heading-2">Key Updates</h2>Commercial momentum continues to be driven by DefenCath, which is seeing strong utilization and patient growth among outpatient dialysis customers. CorMedix noted that reimbursement for DefenCath will decline in the second half of 2026 as the Transitional Drug Add-on Payment Adjustment&nbsp;(TDAPA) transitions to a post-TDAPA add-on adjustment, pressuring pricing later in the year.However, the company expects reimbursement to improve in 2027, potentially supporting higher pricing compared to late 2026.On the clinical front, Phase 3 data from the ReSPECT study of REZZAYO antifungal medication is expected in Q2 2026, while enrollment continues in a Phase 3 study of DefenCath in total parenteral nutrition (TPN) patients. CorMedix is also commercializing a portfolio of anti-infective products.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp intraday decline, retail sentiment on Stocktwits flipped to ‘bullish’ from ‘bearish’ a day earlier, amid ‘high’ message volumes. CRMD was among the top trending tickers on the platform.<img src="https://news.stocktwits-cdn.com/CRMD_jpg_84acb69cec.webp" alt="CRMD.jpg">One user questioned the company’s financial outlook.<stembedurl>https://stocktwits.com/Spoonorama/message/641198820</stembedurl>Another user sounded skeptical about the company’s second-half performance.<stembedurl>https://stocktwits.com/Brunoez/message/641203929</stembedurl>Over the past year, the stock has declined about 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mltx-stock-jump-45-in-pre-market-today/cmUbJFWR4Pt">Why Did MLTX Stock Jump 45% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Did CRMD Stock Crash 28% Today?

CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data.

IWO
iShares Russell 2000 Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWO News

IWOiShares Russell 2000 Growth ETF